search
Back to results

SMART: Somatotrophics, Memory, and Aging Research Trial

Primary Purpose

Aging, Mild Cognitive Impairment

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
TH9507 human growth hormone releasing hormone (GHRH)
Sponsored by
University of Washington
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aging focused on measuring Alzheimer's disease, cognition disorders

Eligibility Criteria

55 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Able to give and understand informed consent Able to communicate in English No exclusionary criteria apply Age between 55 and 90 years Independent in their daily living abilities Living at home with a reliable spouse, significant other or caregiver Normal PSA (for men) or mammogram (for women) within one year of study entry The following inclusion criteria will be applied to identify potential MCI participants: Memory complaint that can be corroborated by a study partner Memory test scores meeting the diagnostic criteria for MCI MMSE score greater than 20 The following inclusion criteria will be applied to identify potential normal control participants: Cognitive testing does not indicate MCI MMSE score greater than 28 Exclusion Criteria: Use of medications known to affect the GHRH/GH/IGF-I axis, including transdermal estrogens (use of oral estrogens is not contraindicated) Significant medical illness or organ failure, such as uncontrolled hypertension, diabetes, cardiac disease, cerebrovascular disease, chronic obstructive pulmonary disease, kidney and liver disease Significant neurologic disease that might affect cognition, such as Alzheimer's disease, stroke, Parkinson's disease, multiple sclerosis, severe head injury with loss of consciousness for more than 30 minutes or with permanent neurologic sequelae Personal or strong family history of cancer (especially colon, breast or melanoma) Evidence for pituitary disease by history or physical examination Symptoms or history of carpal tunnel or a positive Phalen's Test Active arthritis Significant current psychiatric illness, such as depression, schizophrenia or an Axis II diagnosis suggestive of an inability to successfully complete the study protocol Current use of an anti-psychotic, anti-depressant, anti-convulsant, anti-coagulant, anxiolytic or sedative Current or planned use of DHEA, testosterone or cognition-enhancing medication (e.g., cholinesterase inhibitors, memantine) Weight greater than 150% ideal body weight Tobacco use, excessive alcohol intake (more than 2 drinks per day), excessive caffeine intake (more than 4 cups of coffee per day) Baseline IGF-I level greater than the mid-range for healthy young adults (250 ng/ml) Meets NINCDS/ADRDA criteria for AD

Sites / Locations

  • University of Washington

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

Outcomes

Primary Outcome Measures

Change in declarative memory, including total recall scores on three tests of memory and on dual task response time (RT), a test of executive function.

Secondary Outcome Measures

Changes in other areas of cognitive function, including other tests of executive function, tests of lexical access, and tests of cognitive and perceptual-motor processing speed.

Full Information

First Posted
November 21, 2005
Last Updated
December 17, 2013
Sponsor
University of Washington
Collaborators
National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00257712
Brief Title
SMART: Somatotrophics, Memory, and Aging Research Trial
Official Title
GHRH: Cognition in Aging and MCI
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Washington
Collaborators
National Institute on Aging (NIA)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the SMART study was to better understand whether the body's own production of growth hormone (GH) would improve memory and problem solving ability, or cognitive function. The study was a double blind, placebo-controlled study of the cognitive effects of growth hormone releasing hormone (GHRH) in healthy older men and women and in those with mild cognitive impairment (MCI).
Detailed Description
There is considerable and compelling evidence from both the animal and human literature that the actions of the somatotrophic hormonal axis (growth hormone releasing hormone/growth hormone/insulin-like growth factor I) have significant and predictable effects on cognitive function (memory and reasoning ability). A preliminary study has recently shown that five months of growth hormone releasing hormone (GHRH) treatment improves cognitive function in healthy older men and women; there is also preliminary evidence that supports the likelihood of a similar effect in individuals diagnosed with MCI. The study sample will include 160 adults, ages 55-90, half of whom will be cognitively healthy normal adults and half of whom will meet diagnostic criteria for Mild Cognitive Impairment (MCI). Each of these groups will contain equal numbers of men and women. The treatment with GHRH will be twenty weeks in duration. In light of the documented interactions between estrogens and GHRH/GH/IGF-I, each of the two study arms will contain equal proportions of women not on estrogen replacement therapy (NERT) and women on oral estrogen replacement therapy (ERT). ERT women will maintain a regular steady dosage of estrogens for at least seven days preceding each assessment Cognitive assessments to evaluate treatment-related changes in memory and thinking abilities, as well as blood collection to evaluate several biomarkers of interest, will be performed at baseline, 10 and 20 weeks of treatment, and ten weeks post-treatment. In addition there will be five medication and symptom monitoring visits during the treatment period. The study hypotheses are: H1: Healthy, cognitively normal older men and women treated with GHRH will show beneficial effects in cognitive function, including measures of memory, relative to placebo treated subjects. H2: MCI patients treated with GHRH will show beneficial effects in cognitive function, including measures of memory, relative to placebo treated MCI patients. H3: Changes in insulin-like-growth factor (IGF-I) will predict changes in cognition both for normal older adults and for MCI patients treated with GHRH.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aging, Mild Cognitive Impairment
Keywords
Alzheimer's disease, cognition disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
151 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
TH9507 human growth hormone releasing hormone (GHRH)
Intervention Description
1mg subcutaneous injection given daily for 20 weeks
Primary Outcome Measure Information:
Title
Change in declarative memory, including total recall scores on three tests of memory and on dual task response time (RT), a test of executive function.
Time Frame
Baseline, 10, 20, and 30 weeks
Secondary Outcome Measure Information:
Title
Changes in other areas of cognitive function, including other tests of executive function, tests of lexical access, and tests of cognitive and perceptual-motor processing speed.
Time Frame
Baseline, 10, 20, and 30 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Able to give and understand informed consent Able to communicate in English No exclusionary criteria apply Age between 55 and 90 years Independent in their daily living abilities Living at home with a reliable spouse, significant other or caregiver Normal PSA (for men) or mammogram (for women) within one year of study entry The following inclusion criteria will be applied to identify potential MCI participants: Memory complaint that can be corroborated by a study partner Memory test scores meeting the diagnostic criteria for MCI MMSE score greater than 20 The following inclusion criteria will be applied to identify potential normal control participants: Cognitive testing does not indicate MCI MMSE score greater than 28 Exclusion Criteria: Use of medications known to affect the GHRH/GH/IGF-I axis, including transdermal estrogens (use of oral estrogens is not contraindicated) Significant medical illness or organ failure, such as uncontrolled hypertension, diabetes, cardiac disease, cerebrovascular disease, chronic obstructive pulmonary disease, kidney and liver disease Significant neurologic disease that might affect cognition, such as Alzheimer's disease, stroke, Parkinson's disease, multiple sclerosis, severe head injury with loss of consciousness for more than 30 minutes or with permanent neurologic sequelae Personal or strong family history of cancer (especially colon, breast or melanoma) Evidence for pituitary disease by history or physical examination Symptoms or history of carpal tunnel or a positive Phalen's Test Active arthritis Significant current psychiatric illness, such as depression, schizophrenia or an Axis II diagnosis suggestive of an inability to successfully complete the study protocol Current use of an anti-psychotic, anti-depressant, anti-convulsant, anti-coagulant, anxiolytic or sedative Current or planned use of DHEA, testosterone or cognition-enhancing medication (e.g., cholinesterase inhibitors, memantine) Weight greater than 150% ideal body weight Tobacco use, excessive alcohol intake (more than 2 drinks per day), excessive caffeine intake (more than 4 cups of coffee per day) Baseline IGF-I level greater than the mid-range for healthy young adults (250 ng/ml) Meets NINCDS/ADRDA criteria for AD
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael V. Vitiello, PhD
Organizational Affiliation
University of Washington
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Suzanne Barsness, RN,MSN,CCRC
Organizational Affiliation
University of Washington
Official's Role
Study Director
Facility Information:
Facility Name
University of Washington
City
Seattle
State/Province
Washington
ZIP/Postal Code
98195
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
14610297
Citation
Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003 Oct;22(1):41-8. doi: 10.1385/ENDO:22:1:41.
Results Reference
background
PubMed Identifier
16399214
Citation
Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006 Feb;27(2):318-23. doi: 10.1016/j.neurobiolaging.2005.01.010. Epub 2005 Mar 23.
Results Reference
background
PubMed Identifier
23689947
Citation
Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, Merriam GR, Otto RK, Novotny EJ, Vitiello MV. Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013 Jul;70(7):883-90. doi: 10.1001/jamaneurol.2013.1425.
Results Reference
derived
PubMed Identifier
22869065
Citation
Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012 Nov;69(11):1420-9. doi: 10.1001/archneurol.2012.1970.
Results Reference
derived

Learn more about this trial

SMART: Somatotrophics, Memory, and Aging Research Trial

We'll reach out to this number within 24 hrs